About: COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making
Creator	Kesari, Santosh Reid, Tony Larson, Christopher Caroen, Scott Com, Boronsky@epicentrx Dobalian, Vaughn Goyal, Sharad Hammond, Terese Hedjran, Farah Lybeck, Michelle Oronsky, Arnold Oronsky, Bryan Ray, Carolyn
Source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious zoonotic pathogen that has exacted heavy public health, social and economic tolls. In February 2020, the World Health Organization acronymed the disease caused by SARS-CoV-2 as COVID-19, for coronavirus disease 2019. The number of confirmed COVID-19 infections, which has been detected in at least 103 countries, has reached 1,970,225 worldwide as of April 14, 2020 with 124,544 deaths, according to the U.S. Centers for Disease Control and Prevention (CDC) Sitammagari et al. (2020) [1]. Many cases of COVID-19 resolve quickly. However, the disease, which, like other respiratory pathogens that cause common cold symptoms is believed to be transmitted through respiratory droplets. Infection with COVID-19 can also lead to significant morbidity and death; this is particularly the case for cancer patients. Moreover, because the signs and symptoms of COVID-19 are easily misattributed to the sequelae of cancer itself, such as pulmonary embolism, or its treatment, such as nausea and diarrhea, diagnosis may be delayed or missed. Potential COVID-19 rule out criteria, based on the Wells' criteria for pulmonary embolism, another protean disease entity, are provided as a decision-making aid. This review summarizes the current understanding of the transmission, clinical presentation, diagnosis and differential diagnosis, pathogenesis, rationale to treat the cancer or not, treatment and prevention of COVID-19 with an emphasis on implications in cancer.
has issue date	2020-08-20(xsd:dateTime)
bibo:doi	10.1016/j.bbcan.2020.188412
bibo:pmid	32827582
has license	no-cc
sha1sum (hex)	b0178d9b299b87072906d251e46ae84e4940815c
schema:url	https://doi.org/10.1016/j.bbcan.2020.188412
resource representing a document's title	COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making
has PubMed Central identifier	PMC7438345
has PubMed identifier	32827582
schema:publication	Biochim Biophys Acta Rev Cancer
resource representing a document's body	covid:b0178d9b299b87072906d251e46ae84e4940815c#body_text
is schema:about of	named entity 'respiratory failure' named entity 'angiotensin converting enzyme (ACE) inhibitors' named entity 'nucleocapsid' named entity 'comorbidity' named entity 'respiratory syncytial virus' named entity 'HCoV NL63' named entity 'SARS-CoV-2' named entity 'incubation period' named entity 'vinorelbine' named entity 'COVID' named entity 'COVID' named entity 'Preventive measures' named entity 'sore throat' named entity 'acute lung injury' named entity 'SARS-CoV-2' named entity 'metastatic disease' named entity 'index of suspicion' named entity 'comorbidities' named entity 'animal models' named entity 'viruses' named entity 'Nucleocapsid' named entity 'neutropenic fever' named entity 'sequelae' named entity 'SARS-CoV' named entity 'HCoV HKU1' named entity 'biopsies' named entity 'SARS-CoV-2' named entity 'ACE-2' named entity 'temsirolimus' named entity 'epithelia' named entity 'viral entry' named entity 'arbidol' named entity 'comorbidities' named entity 'high-risk' named entity 'SARS-CoV-2' named entity 'United States' named entity 'fatigue' named entity 'vasoprotective' named entity 'comorbid' named entity 'short supply' named entity 'arrythmias' named entity 'bortezomib' named entity 'COVID-19' named entity 'virus' named entity 'oxygen therapy' named entity 'Legionella pneumophila' named entity 'COVID' named entity 'receptor-mediated endocytosis' named entity 'ACE-2' named entity 'patient isolation' named entity 'hemoptysis' named entity 'influenza' named entity 'SARS-CoV-2' named entity 'favipiravir' named entity 'inflammation' named entity 'sunitinib' named entity 'FDA' named entity 'vaccination' named entity 'panel testing' named entity 'quarantine' named entity 'gastrointestinal' named entity 'cardiovascular disease' named entity 'SARS-CoV-2' named entity 'acute infection' named entity 'COPD exacerbation' named entity 'receptor' named entity 'vaccines' named entity 'Reverse Transcriptase Polymerase Chain Reaction' named entity 'adenovirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software